Donepezil Hydrochloride Tablet
Product Images NDC 71335-2065

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 71335-2065). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1. Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing 24 Weeks Of Treatment. (Donepezil Fig1)

A line graph showing mean change from baseline in ADAS-cog scores over weeks of drug treatment for Donepezil Hydrochloride 5 mg/day, 10 mg/day, and Placebo groups. The y-axis indicates clinical improvement or decline, with time on the x-axis spanning 0 to 30 weeks. Error bars represent standard error (SE) for each data point.*

FDA Label Image

Figure 10. Cumulative Percentage Of Patients Completing 6 Months Of Double-blind Treatment With Particular Changes From Baseline In Adcs-adl-severe Scores. (Donepezil Fig10)

A line graph showing cumulative percentage of patients versus ADCS-ADL change from baseline. Two curves represent Donepezil Hydrochloride 10 mg/day and placebo, with Donepezil generally showing a higher cumulative percentage at more negative ADCS-ADL changes, indicating greater change from baseline compared to placebo.*

FDA Label Image

Figure 11. Time-course Of The Change From Baseline In Sib Score For Patients Completing 24 Weeks Of Treatment. (Donepezil Fig11)

A line graph depicting the SIB (Severe Impairment Battery) change from baseline LS mean ±SE over 24 weeks of drug treatment for Donepezil Hydrochloride at doses of 10 mg/day and 23 mg/day. The vertical axis indicates clinical improvement above baseline and clinical decline below baseline. The 23 mg/day dose shows a greater positive change compared to the 10 mg/day dose throughout the treatment period.*

FDA Label Image

Figure 12. Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline Sib Scores. (Donepezil Fig12)

A line graph showing the cumulative percentage of patients on the y-axis and SIB (Severe Impairment Battery) change from baseline on the x-axis. Two treatment groups are compared: Donepezil Hydrochloride 23 mg/day and Donepezil Hydrochloride 10 mg/day. The data depict the distribution of patient responses in terms of SIB score changes over time.*

FDA Label Image

Figure 13. Frequency Distribution Of Cibic-plus Scores At Week 24. (Donepezil Fig13)

Bar chart comparing percentage of patients by CIBIC-plus rating for Donepezil Hydrochloride 23 mg/day and 10 mg/day. Ratings range from Markedly Improved to Markedly Worse, showing varying patient response levels for the two dosages.*

FDA Label Image

Figure 2. Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline Adas-cog Scores. The Percentages Of Randomized Patients Who Completed The Study Were: Placebo 80%, 5 mg/day 85%, And 10 mg/day 68%. (Donepezil Fig2)

A cumulative percentage graph showing patient response change from baseline on the X-axis and cumulative percentage of patients on the Y-axis. It compares placebo, Donepezil Hydrochloride 5 mg, and Donepezil Hydrochloride 10 mg groups, illustrating changes over time with a focus on ADAS-cog scores and the percentage of patients experiencing specific point changes.*

FDA Label Image

Figure 3. Frequency Distribution Of Cibic-plus Scores At Week 24. (Donepezil Fig3)

A bar chart showing the percentage of patients by CIBIC-plus Rating categories comparing Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo groups. The categories range from markedly improved to markedly worse, illustrating patient outcomes for each treatment group.*

FDA Label Image

Figure 4. Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing The 15-week Study. (Donepezil Fig4)

A line graph depicting ADAS-cog mean change from baseline over 15 weeks of treatment comparing Donepezil Hydrochloride 5 mg/day, Donepezil Hydrochloride 10 mg/day, and placebo groups. The y-axis represents change with clinical improvement upward and decline downward; x-axis shows weeks of drug treatment. Donepezil groups show clinical improvement, while placebo shows decline.*

FDA Label Image

Figure 5. Cumulative Percentage Of Patients With Specified Changes From Baseline Adas-cog Scores. The Percentages Of Randomized Patients Within Each Treatment Group Who Completed The Study Were: Placebo 93%, 5 mg/day 90%, And 10 mg/day 82%. (Donepezil Fig5)

A cumulative percentage curve chart showing the change from baseline in patients across three groups: Donepezil Hydrochloride 10 mg/day, Donepezil Hydrochloride 5 mg/day, and placebo. The x-axis represents change from baseline in ADAS-cog scores, and the y-axis represents the cumulative percentage of patients. The graph includes vertical lines indicating 7-point and 4-point changes and a table summarizing percentage changes at different points (-7, -4, 0) for each treatment group.*

FDA Label Image

Figure 6. Frequency Distribution Of Cibic-plus Scores At Week 12. (Donepezil Fig6)

A bar chart displaying the distribution of patient outcomes based on CIBIC-plus ratings for Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo groups. The x-axis lists categories from markedly improved to markedly worse, and the y-axis shows the percentage of patients in each category, illustrating comparative efficacy and patient response rates.*

FDA Label Image

Figure 7. Time Course Of The Change From Baseline In Sib Score For Patients Completing 6 Months Of Treatment. (Donepezil Fig7)

A line graph depicting SIB (Severe Impairment Battery) Change from Baseline (Mean ±SE) over 6 months of drug treatment. It compares Donepezil Hydrochloride 10 mg/day and placebo. The y-axis shows SIB change with indications for clinical improvement and decline, while the x-axis represents months of treatment (0, 3, 6). Donepezil shows an increase from baseline, placebo shows slight decline.*

FDA Label Image

Figure 8. Cumulative Percentage Of Patients Completing 6 Months Of Double-blind Treatment With Particular Changes From Baseline In Sib Scores. (Donepezil Fig8)

A cumulative percentage plot comparing Donepezil Hydrochloride 10 mg/day and placebo on SIB (Severe Impairment Battery) change from baseline in patients. The x-axis shows SIB change from baseline (negative values indicating decline), and the y-axis shows cumulative percentage of patients. Donepezil shows a greater shift left compared to placebo, indicating more improvement or less decline.*

FDA Label Image

Figure 9. Time Course Of The Change From Baseline In Adcs-adl-severe Score For Patients Completing 6 Months Of Treatment. (Donepezil Fig9)

A line graph showing mean change from baseline over 6 months of drug treatment, comparing Donepezil Hydrochloride 10 mg/day versus placebo on the ADCs-ADL scale. The x-axis represents months of drug treatment (0, 3, and 6), and the y-axis depicts ADCs-ADL change from baseline with clinical improvement and decline indicated. Donepezil shows less decline compared to placebo.*

FDA Label Image

Chemical Structure (Donepezil Str)

Chemical structure of Donepezil Hydrochloride, showing its molecular arrangement including methoxy groups, a piperidine ring, and a phenyl group with the hydrochloride salt.*

FDA Label Image

Label (Lbl713352065)

Donepezil 5 mg Tablet packaging label, comparing it to Aricept 5mg Tablet by Elysium Pharmaceuticals Limited. The label indicates it is a white round tablet with lot number 1523487 and is for prescription use only. It includes storage instructions to keep at 20°-25°C (68°-77°F) and to keep out of reach of children. Packaged by Bryant Ranch Prepack in Burbank, CA. The NDC on the label is 71335-2065-1.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.